JPMorgan Chase & Co. cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 2.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 136,600 shares of the medical research company’s stock after selling 2,964 shares during the quarter. JPMorgan Chase & Co.’s holdings in Charles River Laboratories International were worth $29,765,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the stock. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of Charles River Laboratories International by 417.3% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,288 shares of the medical research company’s stock valued at $253,000 after purchasing an additional 1,039 shares during the last quarter. Belpointe Asset Management LLC raised its stake in Charles River Laboratories International by 8.7% in the 4th quarter. Belpointe Asset Management LLC now owns 1,178 shares of the medical research company’s stock valued at $257,000 after acquiring an additional 94 shares during the period. CIBC Private Wealth Group LLC increased its position in shares of Charles River Laboratories International by 1.5% during the third quarter. CIBC Private Wealth Group LLC now owns 103,472 shares of the medical research company’s stock valued at $20,364,000 after buying an additional 1,539 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Charles River Laboratories International by 6.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,059 shares of the medical research company’s stock worth $2,767,000 after acquiring an additional 804 shares in the last quarter. Finally, Banco Bilbao Vizcaya Argentaria S.A. increased its position in shares of Charles River Laboratories International by 4.7% in the fourth quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 1,270 shares of the medical research company’s stock valued at $277,000 after acquiring an additional 57 shares during the period. 97.80% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In related news, EVP Joseph W. Laplume sold 345 shares of the company’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $190.39, for a total transaction of $65,684.55. Following the completion of the sale, the executive vice president now directly owns 24,026 shares in the company, valued at approximately $4,574,310.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.30% of the company’s stock.
Analyst Ratings Changes
Charles River Laboratories International Stock Down 2.7 %
Shares of CRL opened at $197.68 on Monday. The stock has a fifty day moving average of $196.46 and a 200-day moving average of $214.87. Charles River Laboratories International, Inc. has a 52 week low of $181.22 and a 52 week high of $262.00. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.21 and a current ratio of 1.48. The stock has a market capitalization of $10.12 billion, a price-to-earnings ratio of 20.44, a PEG ratio of 1.37 and a beta of 1.34.
Charles River Laboratories International (NYSE:CRL – Get Rating) last issued its earnings results on Thursday, May 11th. The medical research company reported $2.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.19. The business had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $988.10 million. Charles River Laboratories International had a net margin of 12.13% and a return on equity of 20.12%. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.31 earnings per share for the current fiscal year.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.
Featured Stories
- Get a free copy of the StockNews.com research report on Charles River Laboratories International (CRL)
- A 7% Yield and 50% Upside?! Wall Street Digs Rio Tinto
- FuelCell Is Back To Realistic Valuation
- MarketBeat Week in Review – 6/4 – 6/9
- Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition
- Tax Software Specialist Vertex In Buy Zone After Base Breakout
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
